These preliminary results, though reassuring, need validation in larger cohorts, especially due to the narrow therapeutic range of tacrolimus and the risk for graft rejection in undertreatment
To minimize them, doctors typically start with a low dose and gradually increase it over time
A senior in Vero Beach near Indian River Boulevard may use a different pharmacy network than someone in Greenacres near Jog Road , Port St
Bert said
A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026
Glutathione is the most abundant intracellular antioxidant, playing a crucial role in maintaining our health